Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

NCT01329354 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
38
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Collaborators